Changes in Cytokine Levels After Dextrose Injection in Stage IV Knee Osteoarthritis

• Status: Unknown status
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Twenty participants with severe arthritis will be enrolled. For the first week participants will either be injected with dextrose or just have fluid withdrawn for testing. The remaining participants will be given dextrose injection at the end of the week. After one week dextrose injections will be given at one, two, three, four, five, and six months. Fluid will be withdrawn from the knee at time zero, one week, and three months. The hypothesis is that dextrose injection will cause a change in proteins in the knee consistent with improved repair signals, along with improving knee pain and function. .

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fisiatria y Traumatología
• Collaborator: American Association of Orthopaedic Medicine

Criteria

Inclusion Criteria:

• Knee pain for at least 6 months.

• Clinically diagnosed knee osteoarthritis.

• Weight-bearing radiograph consistent with high-grade medial compartment cartilage loss (Kellgren-Lawrence Grading Scale level IV).

• Confirmation of exposed subchondral bone by high-resolution knee ultrasonography.

Exclusion Criteria:

• Anticoagulation therapy.

• Inflammatory or post-infectious knee arthritis.

• Systemic inflammatory conditions.

• Knee flexion of less than 100 degrees.

• Knee extension of less than 165 degrees.

• Any Valgus

• Varus more than 15 degrees.

• Any knee injection in the past 3 months.

• BMI more than 40

• Gross synovial folds on ultrasound

• Elevation of sed rate, C reactive protein, rheumatoid factor or antinuclear antibody.